NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Guidance development

MT217 The PLASMA system for transurethral resection and haemostasis of the prostate

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

Medical technology consultation document

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
Yes. Age was identified as an issue during the scoping process in terms of increased complications with age after TURP. This was discussed at committee and applies to all TURP procedures, not just PLASMA.

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?
No

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?
No

Equality impact assessment (guidance development): MT217 The PLASMA system for transurethral resection and haemostasis of the prostate]

© NICE 2020. All rights reserved. Subject to Notice of rights.   Page 1 of 2

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?
No	

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	

6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No	

7.	Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?
Yes. Section 4.16 "Equalities" of the MTCD describes the committee's consideration of age.	

Approved by Technical Adviser: Chris Pomfrett

Date: 10 September 2020

Equality impact assessment (guidance development): MT217 The PLASMA system for transurethral resection and haemostasis of the prostate]

© NICE 2020. All rights reserved. Subject to Notice of rights.   Page 2 of 2